上海民为生物技术有限公司
SHANGHAI MINWEI BIOTECHNOLOGY CO.,LTD

T2 DM

Obesity
Hyperlipidemia
Others
LAGMA™ directed screening system

Pipelines

Product Development Process

Drug Development


Research Areas

Technology Platforms

ReceIND approved! The National Medical Products Administration has officially approved Shanghai Minwei Biotechnology's MWX401 injection for clinical trials.
2026-03
News Center
ABOUT US

Shanghai Minwei Biotechnology Co., Ltd. was founded in 2021 and is located in Zhoupu Town, Zhangjiang Science City, Pudong New Area, Shanghai, an area known for its concentration of innovative biopharmaceutical and medical device research and development companies. The company specializes in the innovation and platform development of cutting-edge "multi-core large molecule biopharmaceuticals," aiming to create globally competitive novel drugs.

At present, Minwei has a number of research and development pipelines, and nearly 20 clinical approvals at home and abroad. One of the projects has completed phase II multi-center clinical trials for two indications, and several projects have carried out phase I clinical trials at the same time.

     


hr@minweibiotech.com
021-20961910
Building No.13, Zhangjiang Gene Island, Lane 889, Ziping Road, Zhoupu Town, Pudong new district, Shanghai City
|
|
|
|